Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, primarily used as oral glucose-lowering agents in type 2 diabetes, have shown benefits in weight reduction, blood pressure control, and improved insulin resistance and glucose tolerance [4]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.